Gilead

Gilead, is a leader in next generation antibody-drug conjugate (ADC) technology, committed to helping people with hard-to-treat cancers. The impossible is simply what hasn’t been achieved yet. Gilead’s research and development program is focused on what’s next. Their goal is to discover, identify and evaluate investigational compounds that show potential to advance the treatment of life-threatening diseases. For more information, visit: https://www.gilead.com/  

ADC Cast is a non-promotional educational podcast series dedicated to antibody drug conjugates (ADCs) in breast cancer.

Hosted by Dr. Javier Cortes and Professor Peter Schmid, joined by an international panel of experts in ADCs and breast cancer, this educational podcast series unveils invaluable insights into ADCs, shedding light on their developmental history, their distinctive structural features, and mechanisms of action, as well as potential future advancements.

Listen here.